Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CEI: A Clonal Expansion Identifier for T-cell receptor clones following SARS-CoV-2 vaccination.

Journal of immunological methods·2026

Same author

Comparative Efficacy and Safety of Bariatric Surgery and Bariatric Endoscopy for Obesity Management: A Network Meta-Analysis.

Endoscopy international open·2026

Same author

Molecular PET imaging of tumor-associated macrophages in precision oncology.

Cancer letters·2026

Same author

Exosomal transfer of macrophage-derived NEAT1 enhances DNA damage response and confers cisplatin resistance in lung adenocarcinoma via the MAD1L1/p53 axis.

International journal of biological sciences·2026

Same author

Smart hydrogels for overcoming cancer multidrug resistance.

Molecular cancer·2026

Same author

A novel in vitro colorectal cancer model for investigating ABCB1- and ABCC1-mediated multidrug resistance.

Cancer genetics·2026

Search research articles

Related Experiment Video

Updated: Jun 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New developments in anticoagulation for atrial fibrillation.

M Haris U Usman¹, Lawrence A Notaro, Harsh Patel

¹Lankenau Institute for Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096, USA.

Current Treatment Options in Cardiovascular Medicine

|September 26, 2008

Summary

New anticoagulants may replace warfarin for stroke prevention in atrial fibrillation (AF). While effective, warfarin management is complex, prompting research into alternatives like dabigatran, rivaroxaban, and apixaban.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: Jun 30, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

Cardiology
Pharmacology
Neurology

Background:

Patients with atrial fibrillation (AF) have a fivefold increased risk of stroke compared to controls.
Warfarin is an effective anticoagulant for stroke prevention in AF, reducing incidence by two-thirds.
Warfarin management is complex, limiting its use to a subset of patients without contraindications.

Purpose of the Study:

To review emerging anticoagulant agents for stroke prevention in atrial fibrillation.
To compare the efficacy and development status of novel anticoagulants against warfarin.

Main Methods:

Review of clinical development data for direct thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban).
Evaluation of a novel vitamin K antagonist (ATI-5923) for its potential benefits over warfarin.
Comparative analysis of dosing strategies and clinical trial designs for new agents.

Main Results:

Dabigatran, rivaroxaban, and apixaban are advanced in development as potential warfarin alternatives.
These novel agents appear effective, with no clear mechanistic superiority over each other.
ATI-5923 demonstrates warfarin-like benefits with potentially fewer drug interactions and reduced monitoring needs.

Conclusions:

Novel anticoagulants show promise for stroke prevention in AF, potentially simplifying management.
ATI-5923 presents a competitive alternative to both warfarin and newer agents.
Further trials are necessary to definitively establish the efficacy and place of these agents in AF management.